Gender and Body Mass Index-Related Serum Level of Adipokines and Metabolic Syndrome Components in Bipolar Patients who received Lithium and Valproic Acid

2021 ◽  
pp. 1-9
Author(s):  
Majid Marjani ◽  
Neda Dolab ◽  
Mohammad Zaman Kamkar ◽  
Taghi Amiriani ◽  
Jale Yuzugulen ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Valproic Acid ◽  
Serum Level ◽  
Body Mass ◽  
Bipolar Patients ◽  
Metabolic Syndrome Components

scholarly journals Consistently Stable or Decreased Body Mass Index in Young Adulthood and Longitudinal Changes in Metabolic Syndrome Components

Circulation ◽  
2007 ◽  
Vol 115 (8) ◽  
pp. 1004-1011 ◽  
Author(s):  
Donald M. Lloyd-Jones ◽  
Kiang Liu ◽  
Laura A. Colangelo ◽  
Lijing L. Yan ◽  
Liviu Klein ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Body Mass ◽  
Young Adulthood ◽  
Longitudinal Changes ◽  
Metabolic Syndrome Components

PPARγ Pro12Ala Polymorphism Influences the Relationship between Dietary Fat Intake, Adiposity and Lipid Profile in Patients with Type 2 Diabetes

2018 ◽  
Vol 88 (5-6) ◽  
pp. 263-269 ◽  
Author(s):  
Fariba Koohdani ◽  
Gity Sotoudeh ◽  
Zahra Kalantar ◽  
Anahita Mansoori
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Body Mass ◽  
Dietary Fat ◽  
Fat Intake ◽  
Pro12ala Polymorphism ◽  
Dietary Fat Intake ◽  
Metabolic Syndrome Components

Abstract. Background: Peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala polymorphism (rs1801282) has been associated with metabolic syndrome components in some studies. Moreover, the PPARγ gene may mediate the physiological response to dietary fat intake in a ligand-dependent manner. Methods: Metabolic syndrome components (body mass index, waist circumference, and lipid profile) were determined in 290 type 2 diabetes mellitus patients in a cross-sectional study. DNA genotyping for determining PPARγ Pro12Ala polymorphism was conducted using the polymerase chain reaction-restriction length polymorphism method. A semi-quantitative food frequency questionnaire was used to assess the participants’ dietary intakes in the previous year. Results: There were significant differences between the two genotype groups of PPARγ Pro12Ala polymorphism, Ala carriers (Pro/Ala + Ala/Ala) versus non-Ala carriers (Pro/Pro), in terms of mean body mass index (p = 0.04) and waist circumference (p = 0.02). Below the median percentage of energy from monounsaturated and polyunsaturated fatty acids, Ala carriers had a higher body mass index (p = 0.01) compared to non-Ala carriers. Furthermore, a significant interaction between this single-nucleotide polymorphism and polyunsaturated fatty acids intake on serum triglyceride levels (p = 0.01) was seen, and in higher polyunsaturated fatty acids intake (≥ median) Ala carriers had lower triglyceride levels than non-Ala carriers (p = 0.007). Conclusions: The findings of the current study support a significant association between PPARγ Pro12Ala polymorphism and metabolic syndrome components, and they suggest that this polymorphism can modulate the biological response of dietary fat intake on body mass index and triglyceride levels.

Body mass index status is effective in identifying metabolic syndrome components and insulin resistance in Pacific Island teenagers living in New Zealand

Metabolism ◽  
2008 ◽  
Vol 57 (4) ◽  
pp. 511-516 ◽  
Author(s):  
Andrea M. Grant ◽  
Finau K. Taungapeau ◽  
Kirsten A. McAuley ◽  
Rachael W. Taylor ◽  
Sheila M. Williams ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
New Zealand ◽  
Body Mass ◽  
Pacific Island ◽  
Body Mass Index Status ◽  
Metabolic Syndrome Components

The Prognostic Significance of Body Mass Index and Metabolic Parameter Variabilities in Predialysis CKD: A Nationwide Observational Cohort Study

2021 ◽  
pp. ASN.2020121694
Author(s):  
Sehoon Park ◽  
Semin Cho ◽  
Soojin Lee ◽  
Yaerim Kim ◽  
Sanghyun Park ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Body Mass ◽  
Metabolic Parameters ◽  
Metabolic Parameter ◽  
Content Type ◽  
All Cause Mortality ◽  
Metabolic Syndrome Components ◽  
Worse Prognosis

BackgroundThe association between variabilities in body mass index (BMI) or metabolic parameters and prognosis of patients with CKD has rarely been studied.MethodsIn this retrospective observational study on the basis of South Korea’s national health screening database, we identified individuals who received ≥3 health screenings, including those with persistent predialysis CKD (eGFR <60 ml/min per 1.73 m2 or dipstick albuminuria ≥1). The study exposure was variability in BMI or metabolic parameters until baseline assessment, calculated as the variation independent of the mean and stratified into quartiles (with Q4 the highest quartile and Q1 the lowest). We used Cox regression adjusted for various clinical characteristics to analyze risks of all-cause mortality and incident myocardial infarction, stroke, and KRT.ResultsThe study included 84,636 patients with predialysis CKD. Comparing Q4 versus Q1, higher BMI variability was significantly associated with higher risks of all-cause mortality (hazard ratio [HR], 1.66; 95% confidence interval [95% CI], 1.53 to 1.81), P [for trend] <0.001), KRT (HR, 1.20; 95% CI, 1.09 to 1.33; P<0.001), myocardial infarction (HR, 1.19; 95% CI, 1.05 to 1.36, P=0.003), and stroke (HR, 1.19; 95% CI, 1.07 to 1.33, P=0.01). The results were similar in the subgroups divided according to positive or negative trends in BMI during the exposure assessment period. Variabilities in certain metabolic syndrome components (e.g., fasting blood glucose) also were significantly associated with prognosis of patients with predialysis CKD. Those with a higher number of metabolic syndrome components with high variability had a worse prognosis.ConclusionsHigher variabilities in BMI and certain metabolic syndrome components are significantly associated with a worse prognosis in patients with predialysis CKD.

scholarly journals Obesity and Metabolic Comorbidity in Bipolar Disorder: Do Patients on Lithium Comprise A Subgroup? A Naturalistic Study.

2020 ◽  
Author(s):  
Jake Prillo ◽  
Jocelyn Fotso Soh ◽  
Annemick Dols ◽  
Haley Park ◽  
Serge Beaulieu ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Bipolar Disorder ◽  
Body Mass ◽  
Type Ii Diabetes ◽  
Tertiary Care ◽  
Type Ii ◽  
Wide Range ◽  
Prevalence Of Obesity ◽  
Bipolar Patients

Abstract Background: Bipolar disorders (BD) are associated with increased prevalence of obesity and metabolic syndrome (MetS). Nevertheless, there is a wide range in prevalence estimates, and little is known about the relative contributions of medications, especially lithium. We hypothesized that lithium use is not associated with increased body mass index (BMI), metabolic syndrome, and type II diabetes (DM II), when compared to non-lithium users (those on anticonvulsants (ACs) or second-generation antipsychotics (APs)). Methods: Cross-sectional study of 129 patients aged 18-85 with bipolar disorder, followed at tertiary care clinics in Montreal. Patients using lithium were compared with those not on lithium, for body mass index and metabolic syndrome. Results: The prevalence of obesity and MetS in the sample of lithium-using bipolar patients was 42.4% and 34.9%, respectively, with an average BMI of 29.10 (+/-6.70). Lithium and non-lithium groups did not differ in BMI or prevalence of MetS. However, compared to the non-lithium group, lithium users had lower hemoglobin A1C (5.24 +/- 0.53 versus 6.01 +/- 1.83, U=753.5, p=0.006) and lower triglycerides (1.46 +/- 0.88 versus 2.01 +/-1.25, U=947, p=0.020). Conclusions: There is a high prevalence of obesity and metabolic syndrome among bipolar disorder patients. However, this did not appear to be associated with lithium use, when compared to those not on lithium. The lithium subgroup was also associated with lower prevalence of type II diabetes. Future prospective and intervention studies with larger sample sizes are necessary to further explore the association between lithium and insulin resistance, as well as its underlying mechanisms.

Study Upon the Serum Level of Uric Acid and the Metabolic Syndrome Components

2019 ◽  
Vol 70 (3) ◽  
pp. 1062-1066
Author(s):  
Maria Rada ◽  
Delia Berceanu-Vaduva ◽  
Milan Velimirovici ◽  
Simona Dragan ◽  
Daniel Duda-Seiman ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Uric Acid ◽  
Serum Level ◽  
Abdominal Obesity ◽  
Cardiometabolic Risk ◽  
Serum Levels ◽  
Mean Value ◽  
The Metabolic Syndrome ◽  
Direct Association ◽  
Metabolic Syndrome Components

The serum level of uric acid (UA) appears to be associated with a variety of cardiometabolic risk factors; however, direct association with the metabolic syndrome (MetS) remains controversial. The aim of this study is to investigate the association between serum levels of UA and the components that define MetS, differentiated by gender. 262 patients were enrolled (132 women and 130 men); mean value of the age: 58.7�16 year. Hyperuricemia was considered when the level of serum UA �7mg/dL in men, and � 6mg/dL in women; MetS was defined according to the IDF criteria. The prevalence of MetS in the studied group was 35.11% and the prevalence of hyperuricemia was 16.79%. Men with hyperuricemia had the highest prevalence of abdominal obesity (87.5% vs. 66.32%, p [0.001) and hypertriglyceridemia (65.62% vs. 45.91%, p [ 0.001) versus men with normal level of serum UA. Women with hyperuricemia also had a significantly higher incidence of abdominal obesity (75% vs. 57.51%, p [0.001), hypertriglyceridemia (58.33% vs. 38.33%, p [0.001), decreased HDL (50% vs. 33.33%, p [0.001) and hyperglycemia (66.66% versus 50%, p [0.001) compared to those with normal levels of serum UA. The majority of men with hyperuricemia have more than 4 of the MetS components. Hyperuricemia had a higher prevalence in patients with MetS, it may be considered as a causal factor of MetS. Elevated levels of serum uric acid were significantly more associated with the increasing number of MetS components. Early detection and treatment of hyperuricemia is essential for preventing the metabolic syndrome and its complications.

Sign in / Sign up

Export Citation Format

Share Document